When should warfarin (Coumadin) be preferred over apixaban (Eliquis)?

When to Use Warfarin (Coumadin) Over Apixaban (Eliquis)

Warfarin is the required anticoagulant for patients with mechanical heart valves or moderate-to-severe mitral stenosis, while apixaban (and other DOACs) should be used in nearly all other atrial fibrillation patients. 1, 2, 3, 2

Absolute Indications for Warfarin

Mechanical Heart Valves

• Warfarin is mandatory for all patients with mechanical heart valves 1, 2, 3, 2
• DOACs including apixaban are contraindicated in this population
• Dabigatran specifically caused harm in the RE-ALIGN trial 1, 4
• Target INR: 2.0-3.0 (or 2.5-3.5 for certain mechanical aortic valves) 4

Moderate-to-Severe Mitral Stenosis

• Warfarin remains the only evidence-based option 1, 2, 3, 2
• DOACs were excluded from all major clinical trials in this population
• The hemodynamic characteristics and thrombus formation patterns differ from other AF etiologies

Strong Preference for Warfarin

Antiphospholipid Syndrome (APS)

• Warfarin is strongly preferred over apixaban for thrombotic APS 5
• The ASTRO-APS trial showed concerning stroke rates with apixaban: 6 of 23 patients (26%) on apixaban experienced strokes versus 0 of 25 on warfarin
• This trial was terminated early due to safety concerns
• Target INR: 2.0-3.0

High Risk of GI Bleeding

• Warfarin may be preferred in patients with prior GI bleeding or high GI bleeding risk 6
• Apixaban has lower bleeding rates than warfarin overall, but individual patient factors matter
• Consider warfarin if the patient has active peptic ulcer disease, recent GI bleeding, or high-risk GI lesions

Situations Where Warfarin May Be Considered

End-Stage Renal Disease (ESRD) on Dialysis

• For patients with CrCl <15 mL/min or on dialysis: warfarin or apixaban may be reasonable 1, 3
• Apixaban is the only DOAC with any supporting data in dialysis patients
• Dabigatran, rivaroxaban, and edoxaban are not recommended in ESRD 3
• Recent data suggests apixaban may be safe in severe renal impairment 7, but warfarin remains an acceptable alternative
• The evidence is limited (Class IIb recommendation)

Inability to Maintain Therapeutic Apixaban Levels

• If therapeutic drug monitoring shows consistently subtherapeutic apixaban levels despite appropriate dosing 8
• Warfarin allows INR monitoring to confirm therapeutic anticoagulation
• Consider in patients with malabsorption syndromes or altered GI anatomy (though evidence is limited) 6

Extreme Body Weight

• Obesity >120-150 kg or <50 kg: warfarin may be preferred due to lack of DOAC data 6
• Apixaban dosing is reduced to 2.5 mg twice daily if weight ≤60 kg AND age ≥80 years OR serum creatinine ≥1.5 mg/dL 9
• For extreme obesity, warfarin allows monitoring to ensure adequate anticoagulation

Cost and Access Issues

• Warfarin is significantly less expensive than apixaban
• If cost prohibits DOAC use and the patient can reliably attend INR monitoring, warfarin is appropriate
• Generic warfarin costs pennies per day versus dollars per day for apixaban

When Apixaban is Strongly Preferred

For all other patients with nonvalvular AF, apixaban and other DOACs are recommended OVER warfarin (Class I, Level A) 2, 3, 2:

• Lower rates of stroke and systemic embolism
• Significantly lower rates of major bleeding, particularly intracranial hemorrhage
• Lower all-cause mortality 9
• No INR monitoring required
• Fewer drug-food interactions

Specific Scenarios Favoring Apixaban Over Warfarin

• Poor INR control on warfarin: If time in therapeutic range (TTR) <70%, switch to apixaban 1, 3
• History of intracranial hemorrhage: Apixaban has 51% lower hemorrhagic stroke rate than warfarin 9
• Patient preference for no monitoring: Eliminates need for frequent blood draws
• Polypharmacy: Fewer drug interactions than warfarin
• Dietary restrictions: No vitamin K dietary restrictions needed

Critical Caveats

Switching Between Agents

• When switching from warfarin to apixaban: stop warfarin and start apixaban when INR <2.0 9
• When switching from apixaban to warfarin: overlap with parenteral anticoagulant until INR therapeutic, as apixaban affects INR measurements 9
• Beware the first 60 days after switching: Increased risk of adverse events during transition period 10

Drug Interactions

• Reduce apixaban dose by 50% when combined with strong CYP3A4 AND P-gp inhibitors (ketoconazole, itraconazole, ritonavir) 9
• If already on 2.5 mg twice daily, avoid these combinations entirely 9

Monitoring Requirements

• Warfarin: INR weekly during initiation, then monthly when stable 2, 3, 2
• Apixaban: Assess renal and hepatic function before initiation and at least annually 1, 3

The default position in modern practice is apixaban (or another DOAC) for nonvalvular AF unless one of the specific contraindications or strong preferences for warfarin exists. The burden of proof now lies in justifying warfarin use rather than DOAC use.